GlassScriptPhysician profile
Imran Nizamuddin
NPI 1124587365
$1,395.78
in general payments reported to CMS, 2019-2025
8 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $112 · 2023: $727 · 2024: $244 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.51 |
| Education | $174.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $382.94 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $279.23 | 2023 | Rybrevant |
| Janssen Biotech, INC. | $197.32 | 2022-2023 | Rybrevant |
| Beigene USA, INC. | $150.00 | 2023 | Brukinsa |
| Beone Medicines USA, INC. | $143.18 | 2025 | Tevimbra |
| Cti Biopharma Corp. | $122.78 | 2023 | Vonjo |
| Incyte Corporation | $89.95 | 2023 | |
| Pfizer INC. | $30.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Nizamuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.